Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HYNIC-UBI
- Development stage
- Preclinical
- Lead developer
- Aprin Sama Pharmed
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
HYNIC-UBI (6-hydrazinonicotinamide-ubiquicidin) is a peptide-based radiopharmaceutical active ingredient developed by Aprin Sama Pharmed. It consists of the cationic human antimicrobial peptide fragment ubiquicidin (specifically UBI 29-41) conjugated to the bifunctional chelator HYNIC (6-hydrazinonicotinamide). HYNIC-UBI is designed to be radiolabeled with technetium-99m (99mTc) to form [99mTc-HYNIC]-UBI, a diagnostic imaging agent used in single-photon emission computed tomography (SPECT). The radiotracer targets the anionic cell membranes of viable bacteria, allowing for the non-invasive detection and localization of bacterial infections, such as osteomyelitis and soft tissue infections, and effectively distinguishing them from sterile inflammation.
- Other names
- 6-hydrazinonicotinamide-ubiquicidin 29-41HYNIC-UBI 29-41HYNIC-UBI29-41HYNIC-UBI-29-41HYNIC-ubiquicidinHYNIC-ubiquicidin 29-41HYNIC-ubiquicidin29-41HYNIC-ubiquicidin-29-41
Beyond the preview
Go deeper on HYNIC-UBI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HYNIC-UBI.